Lantheus, a Massachusetts-based developer of radiopharmaceuticals, has agreed to acquire the radiopharma contract development and manufacturing organization (CDMO) Evergreen Theragnostics. Lantheus ...

We recently compiled a list of the 12 Best Low Risk High Growth Stocks to Invest In. In this article, we are going to take a ...

With the aim to add a “revenue generating CDMO arm,” Lantheus Holdings has bought New Jersey-based radiopharmaceutical ...

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

Lantheus is acquiring radiopharmaceutical CDMO Evergreen Theragnostics in a deal worth up to $1 billion, expanding its manufacturing capabilities and drug pipeline. The acquisition includes Octevy, a ...

The deal includes an upfront payment of $250m, with the potential for an additional $752.5m in milestone payments.

Lantheus Holdings is stepping up its game in the radiopharmaceutical space by acquiring Massachusetts-based Evergreen ...

Lantheus Holdings Inc., a radiopharmaceutical healthcare company, announced Tuesday its plans to acquire Evergreen Theragnostics Inc. for up to $1 billion, marking a significant expansion of its ...

ITM's lutetium-containing therapy extended progression-free survival versus everolimus in patients with a specific kind of ...

Massachusetts-based radiopharmaceutical company Lantheus (Nasdaq: LNTH) has announced a plan to acquire clinical-stage ...

Lantheus Holdings Inc. is adding to its portfolio yet again, acquiring a clinical-stage radiopharmaceutical company in a deal ...